SRR10900579
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- INTERFERON_ALPHA_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.300
- IL2_STAT5_SIGNALING+0.200
- INFLAMMATORY_RESPONSE+0.200
- P53_PATHWAY+0.200
- TNFA_SIGNALING_VIA_NFKB+0.200
- APICAL_JUNCTION+0.100
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- CHOLESTEROL_HOMEOSTASIS-0.300
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- MTORC1_SIGNALING-0.300
- MYC_TARGETS_V1-0.300
- NOTCH_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- TGF_BETA_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1402239 | GTEX | — | 0.847 |
| 2 | SRR8518409 | — | D | 0.842 |
| 3 | 7cebd572-2edd-4351-b59e-fb4417a46b9c | — | — | 0.841 |
| 4 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.826 |
| 5 | MNG450 | — | — | 0.819 |
| 6 | R117 | — | — | 0.817 |
| 7 | TCGA-LD-A7W5-01A-22R-A352-07 | — | A | 0.814 |
| 8 | ERR2598295 | fetal | fetal | 0.813 |
| 9 | SRR25617829 | — | D | 0.813 |
| 10 | C3N-02675 | — | cohortSQ1 | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |